Our news section contains recent news on neuroendocrine tumors, upcoming NANETS events and information, and people in our community. Have a suggestion? Please click here to contact us.

2015 NCIS Recipient - Arvind Dasari, MD

The NCIS award focuses on supporting a clinical project as well as the investigator's potential to make future clinical contributions to the neuroendocrine tumor field.  Dr. Dasari is an ideal candidate and his research proposal and objectives show great potential.  This award is in honor of Edda Gomez-Panzani, MD for her dedication and work on behalf of patients living with neuroendocrine tumors.

Practice Changing Phase III Trials Presented at 2015 NANETS Symposium

The results of three recent, practice-changing Phase III clinical trials were presented for the first time in North America at the NANETS symposium which included: (1) TELESTAR (randomized Phase III trial of telotristat vs. placebo in patients with carcinoid syndrome), (2) NETTER-1 (randomized Phase III trial of 177-Lu-DOTATATE vs.

NANETS Members Elect New Leadership for 2016/17

I am pleased to announce the election results, and to both congratulate and extend a warm welcome to the new members of our Board of Directors, Advisory Board, and Nominating Committee.

The results of the 2016/17 elections are as follows:

2015 Young Investigator Grant Recipient - Bryson William Katona, MD, PhD

NANETS congratulates  Bryson William Katona as the 2015 Young Investigator grant recipient for his work on ER stress and the unfolded protein response in neuroendocrine tumor proliferation.

University of Iowa Receives Five-Year, $10.67m Grant to Study NETs


Researchers at the Holden Comprehensive Cancer Center at the University of Iowa received a five-year, $10.67 million Specialized Programs of Research Excellence (SPORE) grant to study neuroendocrine tumors

Lexicon Reports Positive Top-Line Results for Phase 3 Telotristat Etiprate Study

On August 3, 2015 Lexicon Pharmaceuticals, Inc. announced that the pivotal TELESTAR Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. Telotristat etiprate was discovered using Lexicon’s gene science, based on Nobel Prize-winning technology, and is the company’s first discovery to complete a pivotal Phase 3 clinical trial. If approved, telotristat etiprate would be the first oral treatment successfully developed for carcinoid syndrome and the first addition to the standard of care in more than 16 years. (Company Press Release) 

NET Studies Presented at the 2015 ASCO Annual Conference

Recently, two multi-institutional cooperative group trials looked at synergistic uses with common related therapies, moving toward the goal of uncovering new standards of care for neuroendocrine tumors.

NANETS Nominations 2015

An engaged and accountable leadership team with a clear vision for NANETS is critical for the success, growth, and long-term health of our organization.

Over the next few months, the NANETS board, advisory board, and nominating committee will be elected by the NANETS professional membership.

The Nominating Committee is tasked with nominating a slate of candidates for general election. Nominations will be accepted for the following (see description below):

Celebrating Edda Gomez-Panzani

The NANETS Community would like to celebrate the life of Edda Gomez-Panzani, who passed on June 30, 2015.  Edda was instrumental in gaining FDA approval for Somatuline (lanreotide) for NETs patients in December 2014. She loved working with the patient community and spoke at support group meetings around the world since joining Tercica (now owned by Ipsen).

Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors


On May 21, 2015 Novartis announced that the Phase III study of Afinitor® (everolimus) tablets plus best supportive care in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met its primary endpoint: significant extension of progression-free survival (PFS) compared to placebo plus best supportive care. The RADIANT-4 study is part of one of the largest clinical trial programs in NET.